"Psychedelic Science and Radical Healing" — Gül Dölen with Krista Tippett

Why It Matters

The ability of psychedelics to reopen critical periods offers a potentially curative approach to depression and PTSD, challenging the entrenched, drug‑maintenance model of modern psychiatry.

Key Takeaways

• Psychedelics can reopen critical periods for social learning in adults.
• MDMA’s therapeutic effects depend heavily on controlled set and setting.
• Traditional SSRIs treat symptoms, not underlying neuroplasticity mechanisms.
• Psychedelic‑assisted therapy may achieve lasting change after few doses.
• Pharma funding models clash with non‑patentable, short‑course psychedelic treatments.

Summary

The conversation between Krista Tippett and neuroscientist Gül Dölen explores how modern psychedelic research is reshaping our understanding of brain plasticity and mental‑health treatment. Dölen, who leads the Dolan Lab at UC Berkeley, recounts her interdisciplinary journey—from a self‑designed major in neuroscience, linguistics and philosophy to MD‑PhD work on autism—and how a class on drugs, brain and behavior sparked a lifelong focus on psychedelics.

Central to the discussion is the discovery of a “critical period” for social learning that can be reopened in adulthood with compounds such as MDMA, psilocybin and ibogaine. Unlike SSRIs, which merely adjust serotonin levels, psychedelics appear to trigger rapid neuroplasticity, allowing a few guided sessions to produce durable behavioral change. The speakers stress that therapeutic outcomes hinge on set and setting, with clinical environments producing empathogenic, “heart‑opening” effects distinct from recreational use.

Dölen cites her lab’s work on octopuses and the historic imprinting experiments of Conrad Lorenz to illustrate how critical periods have long been recognized across species. She notes that over 7,000 papers have examined these mechanisms, earning three Nobel Prizes, and that current psychedelic trials are revealing how brief drug exposure combined with psychotherapy can rewrite maladaptive social circuits.

If these findings hold, they could upend the pharmaceutical model that relies on chronic, patentable medications and multi‑billion‑dollar phase‑III trials. Investors, clinicians, and regulators must grapple with a paradigm where short‑course, non‑patentable treatments deliver long‑term remission, prompting new funding structures and regulatory pathways for mental‑health care.

Original Description

From Krista: The word “trauma” is used so widely at present, arguably too widely. But it bespeaks a tenor of our shared reality. This episode is a journey inside what I’ve come to see as a parallel universe unfolding, where our species is unlocking knowledge about ourselves and capacities for radical healing of the most extreme trauma and distress. These findings are even giving rise to dramatic healing alliances across political and social lines that are inflamed in the culture at large.

At universities and research laboratories around the U.S. and the world, there are countless clinical studies, yielding results it’s hard not at times to call miraculous — for complex PTSD, long-term addiction, treatment-resistant depression. What I’m talking about are therapeutically-administered treatments with plant medicines and chemical compounds we call psychedelic or empathogenic.

Use those words, and many of us — including me until not that long ago — might become wary. Like all forces of great power, these can cut in every direction — the dark and the light of the human condition. But the conversation you are about to hear, with one of the leading neuroscientists in this field, revolves around serious, important research in settings designed for careful, beneficial human effect. Gül Dölen’s groundbreaking contribution to all of us is in her fascinating insight into what psychedelically-assisted therapies are revealing about the workings of the human brain and the brain’s capacity to change and the human capacity for major transformation altogether. The potential consequences of this science are intimate and civilizational at once. I see them as a stunning ray of hope in a struggling world.

I interviewed Gül Dölen at the 2025 Aspen Ideas Festival.